U

University of Nebraska Medical Center | Cardiovascular Department

Research site
(Unclaimed)
Location
982265 Nebraska Medical Center, Omaha, Nebraska, United States of America

Site insights

Top conditions

Top treatments

cyclophosphamide
doxorubicin hydrochloride
etoposide
vincristine sulfate
cytarabine
Lenalidomide
prednisone
methotrexate
carboplatin
Carboplatin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

48 of 357 total trials

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

The purpose of this Phase 1 study is to evaluate the safety and tolerability of CC-96673 in adult participants with Relapsed or Refractory Non-Hodgki...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: CC-96673

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepine...

Active, not recruiting
Prader-Willi Syndrome
Drug: Placebo oral tablet
Drug: Pitolisant oral tablets

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

The main purpose of this study is to measure how well abemaciclib works in participants with early breast cancer who are taking hormone therapy after...

Active, not recruiting
Breast Neoplasms
Drug: Placebo
Drug: Abemaciclib

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refra...

Enrolling
Systemic Sclerosis
Idiopathic Inflammatory Myopathy
Drug: Fludarabine
Drug: CC-97540

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting
Urothelial Cancer
Drug: Erdafitinib
Drug: Vinflunine

The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose es...

Active, not recruiting
Type 2 Diabetes
T2D
Drug: Insulin Glargine
Drug: Insulin Efsitora Alfa

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Active, not recruiting
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian

This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...

Active, not recruiting
Waldenstrom Macroglobulinemia
Marginal Zone Lymphoma
Drug: Venetoclax
Drug: Rituximab

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Risankizumab SC
Drug: Risankizumab On-Body Injector (OBI)

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Tirzepatide
Drug: Dulaglutide

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Sub...

Active, not recruiting
Inclusion Body Myositis
Drug: ABC008

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evalu...

Active, not recruiting
Eosinophilic Esophagitis
Drug: CC-93538
Other: Placebo

This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple s...

Enrolling
Multiple Sclerosis, Primary Progressive
Drug: Ocrelizumab
Drug: Placebo
Locations recently updated

The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in child...

Enrolling
Cytomegalovirus (CMV)
Drug: Maribavir

The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment a...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab
Drug: Placebo

The primary efficacy objective of this study is to test the hypothesis that DBS-f stimulation (ON) will slow cognitive and functional progression of...

Active, not recruiting
Alzheimer Disease
Device: DBS-f On
Device: DBS Off

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure...

Enrolling
Diastolic Heart Failure
Heart Failure With Preserved Ejection Fraction
Device: OPTIMIZER™ Smart Mini System
Device: Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System

Trial sponsors

Alliance for Clinical Trials in Oncology logo
University of Nebraska logo
C
National Cancer Institute (NCI) logo
Pfizer logo
AbbVie logo
Celgene logo
Memorial Sloan Kettering Cancer Center (MSK) logo
Roche logo
E

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems